以中枢神经系统损害为首发症状的干燥综合征3例报道并文献复习
Report of 3 Cases of SjÖgren’s Syndrome with Central Nervous System Damage as the First Symptom and Review of the Literature
摘要: 目的:探讨以中枢神经系统表现为首发症状的干燥综合征的临床特点,以指导诊断、及时治疗。方法:回顾性分析3例以中枢神经系统表现为首发症状的干燥综合征患者的临床特征、诊疗情况,并结合国内外相关文献进行文献分析。结果:2例患者为中年女性,1例为青年男性。中枢神经系统受累表现分别为脊髓炎、Weber综合征、脑干病变合并脑梗死并继发性癫痫。影像学表现多为颅脑核磁FLAIR高信号及T2WI高信号。治疗上3例患者均用大剂量糖皮质激素,并分别联合吗替麦考酚酯、环磷酰胺、丙种球蛋白治疗,2例治疗后病情好转,1例病情恶化死亡。结论:对不能用其他原因解释的中枢神经系统损害,无论年龄性别均应警惕原发性干燥综合征的可能。重视病史采集及实验室指标检测,以早期诊断、及时治疗,减少患者的致残率和致死率。
Abstract: Objective: To explore the clinical characteristics of Sjögren’s syndrome with central nervous system manifestations as the first symptom to guide diagnosis and timely treatment. Methods: The clinical characteristics, diagnosis and treatment of 3 patients with Sjögren’s syndrome with central nervous system damage as the first symptom were retrospectively analyzed, and literature analysis was conducted based on relevant domestic and foreign literature. Results: Two patients were middle-aged women and one was a young man. The manifestations of central nervous system involvement include myelitis, Weber syndrome, brainstem lesions combined with cerebral infarc-tion and secondary epilepsy. Imaging manifestations are mostly high signal on cranial magnetic resonance imaging FLAIR and high signal on T2WI. All 3 patients were treated with high-dose glu-cocorticoids, combined with mycophenolate mofetil, cyclophosphamide, and immunoglobulin re-spectively. After treatment, the condition improved in two patients and worsened in one patient who ended up with death. Conclusion: For central nervous system damage that cannot be explained by other reasons, one should be alert to the possibility of primary Sjögren’s syndrome, regardless of age and gender, paying attention to medical history collection and laboratory index testing to make early diagnosis and timely treatment, to reduce the morbidity and mortality of the patients.
文章引用:刘保成, 麻贞贞, 白艳艳, 刘洁, 杨清锐, 刘东霞. 以中枢神经系统损害为首发症状的干燥综合征3例报道并文献复习[J]. 临床医学进展, 2024, 14(2): 3723-3730. https://doi.org/10.12677/ACM.2024.142519

参考文献

[1] Fiona André, B.C.B. (2022) Sjögren’s Syndrome. Journal der Deutschen Dermatologischen Gesellschaft, 20, 980-1002. [Google Scholar] [CrossRef] [PubMed]
[2] Ramos-Casals, M., Brito-Zerón, P., Sisó-Almirall, A. and Bosch, X. (2012) Primary Sjogren Syndrome. BMJ, 344, e3821. [Google Scholar] [CrossRef] [PubMed]
[3] Alunno, A., Carubbi, F., Bartoloni, E., Cipriani, P., Giacomelli, R. and Gerli, R. (2019) The Kaleidoscope of Neurological Manifestations in Primary Sjögren’s Syndrome. Clinical and Experimental Rheumatology, 37, 192-198.
[4] Seeliger, T., et al. (2023) Sjögren’s Syndrome with and without Neurological Involvement. Journal of Neurology, 270, 2987-2996. [Google Scholar] [CrossRef] [PubMed]
[5] 杨丹, 乔琳, 赵丽丹. 原发干燥综合征伴发脑梗塞1例报告附文献复习[J]. 北京大学学报, 2016, 48(6): 1077-1080.
[6] Chai, J. and Logigian, E.L. (2010) Neurological Mani-festations of Primary Sjögren’s Syndrome. Current Opinion in Neurology, 23, 509-513. [Google Scholar] [CrossRef
[7] Negrini, S., Emmi, G., Greco, M., et al. (2022) Sjögren’s Syndrome: A Systemic Autoimmune Disease. Clinical and Experimental Medicine, 22, 9-25. [Google Scholar] [CrossRef] [PubMed]
[8] André, F. and Böckle, B.C. (2022) Sjögren’s Syndrome. Journal der Deutschen Dermatologischen Gesellschaft, 20, 980-1002. [Google Scholar] [CrossRef] [PubMed]
[9] De Seze, J., Delalande, S., Fauchais, A.L., et al. (2006) Myelopathies Secondary to Sjögren’s Syndrome: Treatment with Monthly Intravenous Cyclophosphamide Associated with Corticosteroids. The Journal of Rheumatology, 33, 709-711.
[10] Hagiwara, K., et al. (2008) Upper Motor Neuron Syndrome Associated with Subclinical Sjögren’s Syn-drome. Internal Medicine, 47, 1047-1051. [Google Scholar] [CrossRef] [PubMed]
[11] Zahlane, S., Louhab, N., El Mellakh, M. and Kissani, N. (2016) Anterior Horn Syndrome: A Rare Manifestation of Primary Sjögren’s Syndrome. Joint Bone Spine, 83, 448-450. [Google Scholar] [CrossRef] [PubMed]
[12] Chandra, M.S., et al. (2022) Primary Sjögren’s Syndrome Presenting as Cerebral Venous Thrombosis: A Rare Case. Cureus, 14, E28772. [Google Scholar] [CrossRef] [PubMed]
[13] Ramos-Casals, M., Brito-Zerón, P., Solans, R., et al. (2014) Systemic Involvement in Primary Sjögren’s Syndrome Evaluated by the EULAR-SS Disease Activity Index: Analysis of 921 Spanish Patients (GEAS-SS Registry). Rheumatology (Oxford), 53, 321-331. [Google Scholar] [CrossRef] [PubMed]
[14] Ramos-Casals, M., et al. (2012) Topical and Systemic Medica-tions for the Treatment of Primary Sjögren’s Syndrome. Nature Reviews Rheumatology, 8, 399-411. [Google Scholar] [CrossRef] [PubMed]
[15] Morreale, M., Marchione, P., Giacomini, P., et al. (2014) Neuro-logical Involvement in Primary Sjögren Syndrome: A Focus on Central Nervous System. PLOS ONE, 9, e84605. [Google Scholar] [CrossRef] [PubMed]
[16] Josephs, K.A., Rubino, F.A. and Dickson, D.W. (2004) Nonvasculitic Autoimmune Inflammatory Meningoencephalitis. Neuropathology, 24, 149-152. [Google Scholar] [CrossRef] [PubMed]
[17] Jamilloux, Y., Magy, L., Hurtevent, J.F., et al. (2014) Immunological Profiles Determine Neurological Involvement in Sjögren’s Syndrome. European Journal of Internal Medicine, 25, 177-181. [Google Scholar] [CrossRef] [PubMed]
[18] Sakai, A., Sugawara, Y., Kuroishi, T., Sasano, T. and Sugawara, S. (2008) Identification of IL-18 and Th17 Cells in Salivary Glands of Patients with Sjögren’s Syndrome, and Amplification of IL-17-Mediated Secretion of Inflammatory Cytokines from Salivary Gland Cells by IL-18. The Journal of Immunology, 181, 2898-2906. [Google Scholar] [CrossRef] [PubMed]
[19] Katsifis, G.E., Rekka, S., Moutsopoulos, N.M., Pillemer, S. and Wahl, S.M. (2009) Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjögren’s Syndrome Immunopathogenesis. The American Journal of Pathology, 175, 1167-1177. [Google Scholar] [CrossRef] [PubMed]
[20] Nocturne, G. and Mariette, X. (2013) Advances in Understanding the Pathogenesis of Primary Sjögren’s Syndrome. Nature Reviews Rheumatology, 9, 544-556. [Google Scholar] [CrossRef] [PubMed]
[21] Sarigul, M., et al. (2010) The Numbers of Foxp3+ Treg Cells Are Positively Correlated with Higher Grade of Infiltration at the Salivary Glands in Primary Sjögren’s Syndrome. Lupus, 19, 138-145. [Google Scholar] [CrossRef] [PubMed]
[22] Fan, G., Dai, F., Chen, S., et al. (2021) Neurological Involvement in Patients with Primary Sjögren’s Syndrome. Journal of Clinical Rheumatology, 27, 50-55. [Google Scholar] [CrossRef
[23] Rajagopala, S., Danigeti, G. and Subrahmanyan, D. (2015) An Unusually Dry Story. Indian Journal of Critical Care Medicine, 19, 550-553. [Google Scholar] [CrossRef] [PubMed]
[24] Ichikawa, H., Ishihara, K., Fujimoto, R., et al. (2004) An Autop-sied Case of Sjögren’s Syndrome with Massive Necrotic and Demyelinating Lesions of the Cerebellar White Matter. Journal of the Neurological Sciences, 225, 143-148. [Google Scholar] [CrossRef] [PubMed]
[25] Meheroz, H., Rabadi, S.K. and Brett, D. (2010) Neurological Pic-tures. Primary Sjögren Syndrome Presenting as Neuromyelitis Optica. Journal of Neurology Neurosurgery and Psy-chiatry, 81, 213-214. [Google Scholar] [CrossRef] [PubMed]
[26] Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., et al. (2020) EULAR Recommendations for the Management of Sjögren’s Syndrome with Topical and Systemic Therapies. Annals of the Rheumatic Diseases, 79, 3-18. [Google Scholar] [CrossRef] [PubMed]
[27] Radaelli, M., Moiola, L., Sangalli, F., et al. (2016) Neuromyelitis Optica Spectrum Disorders: Long-Term Safety and Efficacy of Rituximab in Caucasian Patients. Multiple Sclerosis, 22, 511-519. [Google Scholar] [CrossRef] [PubMed]